ArticleCancer research2021
A BRCA1 Coiled-Coil Domain Variant Disrupting PALB2 Interaction Promotes the Development of Mammary Tumors and Confers a Targetable Defect in Homologous Recombination Repair.
Open access · bronzeAbstract read
In one paragraph
Article in Cancer research, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
1.6field-weighted citation impact, top 16% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 17 citations in OpenAlex.
- The BRCA1 coiled-coil domain is dispensable for suppression of tandem duplications and tolerance of FANCM loss.The EMBO journal · 2026Article
- Insights from three decades of BRCA1/2 modeling in mice.Nature genetics · 2026Review
- ComprehensiveFrontiers in cell and developmental biology · 2026Article
- New twist on BRCA1-mediated DNA recombination repair and tumor suppression.Trends in cell biology · 2026Review
- PALB2 and 53BP1 govern post-resection homologous recombination DNA repair.Molecular cell · 2025Article
- BRCA1 and BRCA2: from cancer susceptibility to synthetic lethality.Genes & development · 2025Review
- Proline variants in the BRCA1 coiled-coil domain disrupt folding and binding to PALB2.Protein science : a publication of the Protein Society · 2025Article
- Installation of an Indole on the BRCA1 Disordered Domain Using Triazine Chemistry.Biomolecules · 2024Article
- Defective Homologous Recombination Repair By Up-Regulating Lnc-HZ10/Ahr Loop in Human Trophoblast Cells Induced Miscarriage.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2024Article
- BRCA1 and Its Vulnerable C-Terminal BRCT Domain: Structure, Function, Genetic Mutations and Links to Diagnosis and Treatment of Breast and Ovarian Cancer.Pharmaceuticals (Basel, Switzerland) · 2024Review
- Brca1 Mouse Models: Functional Insights and Therapeutic Opportunities.Journal of molecular biology · 2024Review
- Multiplexed assay of variant effect reveals residues of functional importance in the BRCA1 coiled-coil and serine cluster domains.PloS one · 2023Article
- BRCA1-Dependent and Independent Recruitment of PALB2-BRCA2-RAD51 in the DNA Damage Response and Cancer.Cancer research · 2022Review
Corrections and comments
- Commented on by
Authors and funding
24 authors at 7 institutions in 2 countries.
Emilia M PulverOncode Institute and Division of Molecular Pathology, The Netherlands Cancer Institute, Amsterdam, the Netherlands.ORCID 0000-0001-5748-1835
Chirantani MukherjeeDepartment of Molecular Genetics, Erasmus MC Cancer Institute, Erasmus University Medical Center, Rotterdam, the Netherlands.ORCID 0000-0002-7738-5135
Gerarda van de KampDepartment of Molecular Genetics, Erasmus MC Cancer Institute, Erasmus University Medical Center, Rotterdam, the Netherlands.
Stefan J RoobolDepartment of Molecular Genetics, Erasmus MC Cancer Institute, Erasmus University Medical Center, Rotterdam, the Netherlands.ORCID 0000-0002-3051-4753
Magdalena B RotherDepartment of Human Genetics, Leiden University Medical Center, Leiden, the Netherlands.
Hanneke van der GuldenOncode Institute and Division of Molecular Pathology, The Netherlands Cancer Institute, Amsterdam, the Netherlands.
Roebi de BruijnOncode Institute and Division of Molecular Pathology, The Netherlands Cancer Institute, Amsterdam, the Netherlands.
Maria Valeria LattanzioOncode Institute and Division of Molecular Pathology, The Netherlands Cancer Institute, Amsterdam, the Netherlands.
Eline van der BurgOncode Institute and Division of Molecular Pathology, The Netherlands Cancer Institute, Amsterdam, the Netherlands.
Anne Paulien DrenthOncode Institute and Division of Molecular Pathology, The Netherlands Cancer Institute, Amsterdam, the Netherlands.
Nicole S VerkaikDepartment of Molecular Genetics, Erasmus MC Cancer Institute, Erasmus University Medical Center, Rotterdam, the Netherlands.
Kerstin HahnOncode Institute and Division of Molecular Pathology, The Netherlands Cancer Institute, Amsterdam, the Netherlands.
Sjoerd KlarenbeekExperimental Animal Pathology, The Netherlands Cancer Institute, Amsterdam, the Netherlands.ORCID 0000-0002-1891-1940
Renske de Korte-GrimmerinkPreclinical Intervention Unit, Mouse Clinic for Cancer and Aging (MCCA), The Netherlands Cancer Institute, Amsterdam, the Netherlands.
Marieke van de VenPreclinical Intervention Unit, Mouse Clinic for Cancer and Aging (MCCA), The Netherlands Cancer Institute, Amsterdam, the Netherlands.ORCID 0000-0001-6779-9353
Colin E J PritchardTransgenic Core Facility, Mouse Clinic for Cancer and Aging (MCCA), The Netherlands Cancer Institute, Amsterdam, the Netherlands.ORCID 0000-0001-7848-9377
Ivo J HuijbersTransgenic Core Facility, Mouse Clinic for Cancer and Aging (MCCA), The Netherlands Cancer Institute, Amsterdam, the Netherlands.
Bing XiaDepartment of Radiation Oncology, Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey.
Dik C van GentDepartment of Molecular Genetics, Erasmus MC Cancer Institute, Erasmus University Medical Center, Rotterdam, the Netherlands.ORCID 0000-0003-1473-8148
Jeroen EssersDepartment of Molecular Genetics, Erasmus MC Cancer Institute, Erasmus University Medical Center, Rotterdam, the Netherlands.
Haico van AttikumDepartment of Human Genetics, Leiden University Medical Center, Leiden, the Netherlands.ORCID 0000-0001-8590-0240
Arnab Ray ChaudhuriDepartment of Molecular Genetics, Erasmus MC Cancer Institute, Erasmus University Medical Center, Rotterdam, the Netherlands.
Peter BouwmanOncode Institute and Division of Molecular Pathology, The Netherlands Cancer Institute, Amsterdam, the Netherlands. j.jonkers@nki.nl r.j.p.bouwman@lacdr.leidenuniv.nl.ORCID 0000-0002-9252-5896
Jos JonkersOncode Institute and Division of Molecular Pathology, The Netherlands Cancer Institute, Amsterdam, the Netherlands. j.jonkers@nki.nl r.j.p.bouwman@lacdr.leidenuniv.nl.ORCID 0000-0002-9264-9792
Oncode Institute · NLErasmus MC Cancer Institute · NLCancer Genomics Centre · NLErasmus MC · NLLeiden University Medical Center · NLNetherlands Comprehensive Cancer Organisation · NLRutgers, The State University of New Jersey · US
Funding
Role of PALB2 in the DNA Damage Response and Cancer SuppressionR01CA138804 · NCI · UNIV OF MED/DENT NJ-R W JOHNSON MED SCH · PI XIA, BING · 2009 to 2024
$5.5MRegulation of DNA replication kinetics by BRCA2 after DNA damageR01CA262227 · NCI · RUTGERS BIOMEDICAL AND HEALTH SCIENCES · PI XIA, BING · 2021 to 2025
$1.7MNCI NIH HHS R01 CA138804NCI NIH HHS R01 CA262227ZonMw 91814643
Abstract
The
Indexed as
Gene Expression Regulation, NeoplasticHomologous RecombinationRecombinational DNA RepairAnimalsApoptosisBRCA1 ProteinBRCA2 ProteinCell ProliferationFanconi Anemia Complementation Group N ProteinFemaleMammary Neoplasms, AnimalMiceMice, KnockoutTumor Cells, CulturedTumor Suppressor Protein p53BRCA1 ProteinBrca1 protein, mouseBRCA2 ProteinBRCA2 protein, mouseFanconi Anemia Complementation Group N ProteinPalb2 protein, mouseTrp53 protein, mouseTumor Suppressor Protein p53
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.